GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

GeneTether Therapeutics Inc. is a Canada-based genetic medicines company focused on creating gene editing therapies based on its proprietary GeneTether platform. The Company's platform technology uses a proprietary method to tether donor deoxyribonucleic acid (DNA) templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. By positioning a donor DNA template directly at the site of a double strand break, the Company's GeneTether platform drives the DNA repair process towards homology-directed repair (HDR), a cellular repair mechanism that incorporates the genetic information of a DNA template. It is building a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin. The Company's GeneTether platform may also allow for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases.